Healthcare >> CEO Interviews >> September 13, 2004
JONATHAN E. LIM, MD has served as President and Chief Executive Officer
of Halozyme Therapeutics, Inc., since May 2003, as Director since
October 2003, and as Chairman since April 2004. Prior to Halozyme, Dr.
Lim was a management consultant at McKinsey & Company, where he
specialized in health care, serving a wide range of startups to Fortune
500 companies in the biopharmaceutical, medical products and
payor/provider industries. Prior to McKinsey, Dr. Lim was a recipient of
a National Institutes of Health Postdoctoral Fellowship, during which
time he conducted clinical outcomes research at Harvard Medical School.
He has published articles in peer-reviewed medical journals such as the
Annals of Surgery and the Journal of Refractive Surgery. Dr. Lim's prior
experience includes clinical training in general surgery at the New York
Hospital-Cornell Medical Center and Memorial Sloan-Kettering Cancer
Center. He also was Founder and President of a seed-stage healthcare
company; Founding Editor-in-Chief of the McGill Journal of Medicine; and
conducted basic science and clinical research at the Salk Institute for
Biological Studies and Massachusetts Eye and Ear Infirmary. Dr. Lim is
currently a California-licensed physician and member of the strategic
planning committee of the American Medical Association. He earned his BS
with honors and MS in Molecular Biology from Stanford University, his MD
from McGill University and his MPH in Health Care Management from
Harvard University. Profile
company's technology.
Dr. Lim: Halozyme Therapeutics was founded in 1998 around intellectual
property based on a family of
